ASCO 2009 - A Phase II Study of Sunitinib on a Continuous Dosing Schedule in Patients with Relapsed or Refractory Urothelial Carcinoma - Session Highlights
ORLANDO, FL, USA (UroToday.com) - Sunitinib has demonstrated activity as a second-line agent for patients with advanced urothelial carcinoma (UC) when administered on a 4 week on, 2 week off schedule.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810 UroToday International Journal Correspondence
Privacy Policy | © 2010 UroToday ® All Rights Reserved |
